# Paliperidone

## Invega inj 100mg (=156mg)

| 藥物代碼           | IINV                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|:-------------------|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 適應症             | Acute & maintenance treatment of schizophrenia in adults.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| 副作用             | Cerebrovascular events including stroke. Neuroleptic malignant syndrome, QT prolongation, tardive dyskinesia, hyperglycemia & DM, wt gain, hyperprolactinemia. Orthostatic hypotension & syncope. Leukopenia, neutropenia & agranulocytosis. Cognitive & motor impairment. Seizures, dysphagia, suicide, priapism, TTP. Disruption of body temp regulation. Antiemetic effect. Inj site reactions, somnolence/sedation, dizziness, akathisia & extrapyramidal disorder.                                                                                                                              |
| 禁忌               | Hypersensitivity to paliperidone or risperidone.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| 藥物保存方式       | 室溫                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| 用法用量           | Initial: 234 mg on treatment day 1 followed by 156 mg 1 week later with both doses administered in the deltoid muscle. The second dose may be administered 4 days before or after the weekly time point. Maintenance: Following the 1-week initiation regimen, adjust the dose based on response and tolerability and begin a maintenance dose of 78 to 234 mg every month administered in either the deltoid or gluteal muscle (the 39 mg dose was not studied in schizoaffective disorder trials). The monthly maintenance dose may be administered 7 days before or after the monthly time point. |
| 肝功能異常         | 無需調整劑量                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| 腎功能異常         | 無需調整劑量                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| 懷孕用藥危分級     | 尚未確立                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| 孕期用藥建議       | No (Limited) Human Data - animal data suggest low risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 附帶說明           | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| 哺乳期用藥建議     | No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| 附帶說明           | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| 注射劑給藥建議途徑 | IM                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| 乾粉稀釋液         | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| 輸注點滴液         | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| IVP 用法建議       | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| IVD 用法建議       | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| 注意事項           | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |

## INVEGA inj 150mg (=234mg)

| 藥物代碼           | IINV2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|:-------------------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 適應症             | Acute & maintenance treatment of schizophrenia in adults.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| 副作用             | Cerebrovascular events including stroke. Neuroleptic malignant syndrome, QT prolongation, tardive dyskinesia, hyperglycemia & DM, wt gain, hyperprolactinemia. Orthostatic hypotension & syncope. Leukopenia, neutropenia & agranulocytosis. Cognitive & motor impairment. Seizures, dysphagia, suicide, priapism, TTP. Disruption of body temp regulation. Antiemetic effect. Inj site reactions, somnolence/sedation, dizziness, akathisia & extrapyramidal disorder.                                                                                                                                                                                                                                                   |
| 禁忌               | Hypersensitivity to paliperidone or risperidone.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 懷孕用藥危分級     | 尚未確立                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| 孕期用藥建議       | Compatible - maternal benefit >> embryo-fetal risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| 附帶說明           | Micromedex Pregnancy Rating: Fetal risk cannot be ruled out. Although no structural malformations attributable to risperidone have been reported, the number of exposures is too low to fully assess the embryo–fetal risk. In addition, there is a risk of extrapyramidal and/or withdrawal symptoms in the newborn if the drug is used in the 3rd trimester. Nevertheless, risperidone is indicated for severe debilitating mental disease and the benefits to the mother appear to outweigh the potential embryo–fetal risks. Folic acid 4 mg/day has been recommended for women taking atypical antipsychotics because they may have a higher risk of neural tube defects due to inadequate folate intake and obesity |
| 哺乳期用藥建議     | Contraindicated 哺乳期使用禁忌                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| 附帶說明           | Micromedex Lactation Rating: Infant risk cannot be ruled out.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| 注射劑給藥建議途徑 | IM                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| 乾粉稀釋液         | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| 輸注點滴液         | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| IVP 用法建議       | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| IVD 用法建議       | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| 注意事項           | 1.仿單對於不同注射部位及病患體重建議使用不同的針頭,請參照. 2.請貯存於30°C以下。切勿與任何其它產品或稀釋劑混合使用。                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |

## Invega 3mg extended release

| 藥物代碼           | OINV                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|:-------------------|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 適應症             | Treatment of schizophrenia.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| 副作用             | Cardiac disturbances, arrhythmia, GI disturbances, upper abdominal pain, extrapyramidal disorder, weight increase. Rarely edema, hypersensitivity reactions, dystonia, hypotension, venous thromboembolism.Cardiovascular: Tachycardia (16% geriatric )Endocrine metabolic: Hyperprolactinemia (geriatric, 45% to 49% ), Weight gain (4% to 9% )Gastrointestinal: Constipation (4% to 5% ), Indigestion (5% to 6% )Neurologic: Akathisia (3% to 10% ), Extrapyramidal disease (2% to 20% ), Somnolence (6% to 12% )Respiratory: Nasopharyngitis (2% to 5% ) |
| 禁忌               | Hypersensitivity to risperidone. Congenital long QT syndrome, cardiac arrhythmias. Pre-existing severe GI narrowing. Lactation.                                                                                                                                                                                                                                                                                                                                                                                                                             |
| 懷孕用藥危分級     | 除非治療上需要                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| 孕期用藥建議       | No (Limited) Human Data - animal data suggest low risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| 附帶說明           | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| 哺乳期用藥建議     | No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| 附帶說明           | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| 注射劑給藥建議途徑 | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| 乾粉稀釋液         | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| 輸注點滴液         | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| IVP 用法建議       | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| IVD 用法建議       | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| 注意事項           | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |

